Kainova Therapeutics, a clinical-stage biopharmaceutical company focused on GPCR-modulating therapies for immuno-oncology and inflammation, has announced it has secured $32.0 million in new funding. This capital infusion marks a significant step for the company as it continues to advance its robust pipeline of therapeutic candidates.
Formerly known as Domain Therapeutics, Kainova leverages decades of scientific and medical expertise. The company integrates deep biological knowledge with a proprietary, validated, and end-to-end discovery and development approach. This platform enables Kainova to unlock challenging and underexploited GPCR targets, advancing programs with strong clinical and commercial potential. Key programs include DT-7012, a clinical-stage Treg depleting anti-CCR8 antibody, and DT-9046, a first-in-class biased antagonist of PAR2, alongside additional programs in immune regulation and inflammatory disease.
The $32.0 million in funding will be instrumental in accelerating the development of Kainova's clinical programs and expanding its pipeline. The company, headquartered in North America with operations in France and Australia, plans to use the capital to support ongoing clinical trials and further its strategic initiatives aimed at bringing novel therapies to patients.
As GPCRs re-emerge as next-generation drug targets, Kainova Therapeutics is positioned to lead the field. The company combines scientific mastery with corporate maturity and agility to compete in fast-expanding markets. This investment underscores confidence in Kainova's approach to advancing first-in-class and best-in-class assets.
Kainova Therapeutics remains committed to delivering therapies that create lasting value for patients and partners, driving its mission to transform patient outcomes through innovative science and meaningful partnerships.
